Evidence map›Paper›PMID 41221385›Full record

ReviewWorld journal of nuclear medicine2025

ARTnet Perspectives and Contributions to Theranostics.

Roslyn J Francis, Dale L Bailey, Kathy Willowson, Melissa J Latter, Bridget Chappell, George McGill, Michael S Hofman, Louise Emmett, Andrew M Scott

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Theranostics Implementation: Opportunities and Challenges.World journal of nuclear medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Roslyn J FrancisDepartment of Nuclear Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia.ORCID 0000-0002-6256-1351
Dale L BaileyDepartment of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia.ORCID 0000-0001-9154-7957
Kathy WillowsonDepartment of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia.
Melissa J LatterDepartment of Nuclear Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia.
Bridget ChappellDepartment of Molecular Imaging and Therapy at Austin Health, Melbourne, Australia.
George McGillDepartment of Molecular Imaging, Princess Alexandra Hospital, Brisbane, Australia.
Michael S HofmanProstate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Centre, Melbourne, Australia.
Louise EmmettDepartment of Nuclear Medicine, St Vincent's Hospital, Sydney and Faculty of Medicine, UNSW Sydney, NSW, Australia.
Andrew M ScottDepartment of Molecular Imaging and Therapy at Austin Health, Melbourne, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Theranostics is a rapidly growing field, providing new therapeutic options for cancer patients. Clinical trials have a key role in establishing the efficacy and safety of new treatments and determining impact on patient care. Multicenter clinical trials with radiopharmaceuticals provide robust data to support clinical implementation; however, there are important considerations to ensure high-quality and reliable clinical data. Australasian Radiopharmaceutical Trials Network (ARTnet) is a multidisciplinary clinical trials network established in 2014 to facilitate multicenter clinical trials with radiopharmaceuticals in Australia. Over the last decade, ARTnet has supported impactful, prospective clinical trials through quality activities and engagement. In theranostics, Australia has had a key role in clinical translation and generating evidence for safety and efficacy, resulting in regulatory approval and health care funding internationally. This report describes the development of ARTnet as a clinical trials network, highlighting the intent, current status, and operations of ARTnet, with a particular focus on theranostics.

Indexed as

clinical trialsharmonizationoncologyradiopharmaceuticalstheranostics

Identifiers

PMID41221385
PMCPMC12602080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.